Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 64 entries
Sorted by: Best Match Show Resources per page
Evaluation of a screening test for female college athletes with eating disorders and disordered eating.

Journal of athletic training

Nagel DL, Black DR, Leverenz LJ, Coster DC.
PMID: 16558658
J Athl Train. 2000 Oct;35(4):431-40.

OBJECTIVE: To develop a screening test to detect female college athletes with eating disorders/disordered eating (ED/ DE). No validated eating disorder screening tests specifically for athletes have been available.DESIGN AND SETTING: In this cross-sectional study, subjects from a large...

Cite
Nagel DL, Black DR, Leverenz LJ, et al. Evaluation of a screening test for female college athletes with eating disorders and disordered eating. J Athl Train. 2000;35(4):431-40
Nagel, D. L., Black, D. R., Leverenz, L. J., & Coster, D. C. (2000). Evaluation of a screening test for female college athletes with eating disorders and disordered eating. Journal of athletic training, 35(4), 431-40.
Nagel, D L, et al. "Evaluation of a screening test for female college athletes with eating disorders and disordered eating." Journal of athletic training vol. 35,4 (2000): 431-40.
Nagel DL, Black DR, Leverenz LJ, Coster DC. Evaluation of a screening test for female college athletes with eating disorders and disordered eating. J Athl Train. 2000 Oct;35(4):431-40. PMID: 16558658; PMCID: PMC1323370.
Copy Download .nbib Format: NLM
From model system to clinical medicine: pathophysiologic links of common proteinopathies.

Alzheimer's research & therapy

McMillan PJ, Leverenz JB.
PMID: 20854651
Alzheimers Res Ther. 2010 Sep 17;2(5):26. doi: 10.1186/alzrt50.

Recent clinical evidence suggests that Alzheimer disease (AD), Parkinson disease (PD), and dementia with Lewy bodies (DLB), though distinct neurological disorders, have some common pathological features that may have an impact on the clinical characteristics of these diseases. However,...

Cite
McMillan PJ, Leverenz JB. From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimers Res Ther. 2010;2(5):26doi: 10.1186/alzrt50.
McMillan, P. J., & Leverenz, J. B. (2010). From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimer's research & therapy, 2(5), 26. https://doi.org/10.1186/alzrt50
McMillan, Pamela J, and Leverenz, James B. "From model system to clinical medicine: pathophysiologic links of common proteinopathies." Alzheimer's research & therapy vol. 2,5 (2010): 26. doi: https://doi.org/10.1186/alzrt50
McMillan PJ, Leverenz JB. From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimers Res Ther. 2010 Sep 17;2(5):26. doi: 10.1186/alzrt50. PMID: 20854651; PMCID: PMC2983435.
Copy Download .nbib Format: NLM
Basic Mechanisms in Neurodegenerative Disease: Implications for Behavioral Pathogenesis and Treatment.

Seminars in clinical neuropsychiatry

Borson S, Leverenz JB.
PMID: 10320428
Semin Clin Neuropsychiatry. 1996 Oct;1(4):248-260. doi: 10.1053/SCNP00100248.

Current therapies for neurodegenerative diseases focus primarily on the use of psychotropic drugs to influence their non-cognitive manifestations. In this article, we take a conceptual approach to understanding behavioral syndromes in dementing disorders, with a heuristic emphasis on Alsheimer's...

Cite
Borson S, Leverenz JB. Basic Mechanisms in Neurodegenerative Disease: Implications for Behavioral Pathogenesis and Treatment. Semin Clin Neuropsychiatry. 1996;1(4):248-260doi: 10.1053/SCNP00100248.
Borson, S., & Leverenz, J. B. (1996). Basic Mechanisms in Neurodegenerative Disease: Implications for Behavioral Pathogenesis and Treatment. Seminars in clinical neuropsychiatry, 1(4), 248-260. https://doi.org/10.1053/SCNP00100248
Borson, and Leverenz. "Basic Mechanisms in Neurodegenerative Disease: Implications for Behavioral Pathogenesis and Treatment." Seminars in clinical neuropsychiatry vol. 1,4 (1996): 248-260. doi: https://doi.org/10.1053/SCNP00100248
Borson S, Leverenz JB. Basic Mechanisms in Neurodegenerative Disease: Implications for Behavioral Pathogenesis and Treatment. Semin Clin Neuropsychiatry. 1996 Oct;1(4):248-260. doi: 10.1053/SCNP00100248. PMID: 10320428.
Copy Download .nbib Format: NLM
Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis.

Frontiers in neurology

Blinder T, Lewerenz J.
PMID: 31404257
Front Neurol. 2019 Jul 25;10:804. doi: 10.3389/fneur.2019.00804. eCollection 2019.

Autoimmune encephalitides (AIE) comprise a group of inflammatory diseases of the central nervous system (CNS), which can be further characterized by the presence of different antineuronal antibodies. Recently, a clinical approach for diagnostic criteria for the suspected diagnosis of...

Cite
Blinder T, Lewerenz J. Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis. Front Neurol. 2019;10:804doi: 10.3389/fneur.2019.00804.
Blinder, T., & Lewerenz, J. (2019). Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis. Frontiers in neurology, 10804. https://doi.org/10.3389/fneur.2019.00804
Blinder, Tetyana, and Lewerenz, Jan. "Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis." Frontiers in neurology vol. 10 (2019): 804. doi: https://doi.org/10.3389/fneur.2019.00804
Blinder T, Lewerenz J. Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis. Front Neurol. 2019 Jul 25;10:804. doi: 10.3389/fneur.2019.00804. eCollection 2019. PMID: 31404257; PMCID: PMC6670288.
Copy Download .nbib Format: NLM
Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis.

Movement disorders clinical practice

Hall DA, Stebbins GT, Litvan I, Bordelon Y, Riley DE, Leverenz J, Standaert DG.
PMID: 30363575
Mov Disord Clin Pract. 2015 Oct 20;3(1):65-67. doi: 10.1002/mdc3.12243. eCollection 2016.

INTRODUCTION: PSP is a rare degenerative disorder associated with significant morbidity. Recently, investigations of the etiology and treatment of PSP have been initiated. The aim of the present study was to validate the motor domain of the Progressive Supranuclear...

Cite
Hall DA, Stebbins GT, Litvan I, et al. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Mov Disord Clin Pract. 2015;3(1):65-67doi: 10.1002/mdc3.12243.
Hall, D. A., Stebbins, G. T., Litvan, I., Bordelon, Y., Riley, D. E., Leverenz, J., & Standaert, D. G. (2016). Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Movement disorders clinical practice, 3(1), 65-67. https://doi.org/10.1002/mdc3.12243
Hall, Deborah A, et al. "Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis." Movement disorders clinical practice vol. 3,1 (2016): 65-67. doi: https://doi.org/10.1002/mdc3.12243
Hall DA, Stebbins GT, Litvan I, Bordelon Y, Riley DE, Leverenz J, Standaert DG. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Mov Disord Clin Pract. 2015 Oct 20;3(1):65-67. doi: 10.1002/mdc3.12243. eCollection 2016. PMID: 30363575; PMCID: PMC6178694.
Copy Download .nbib Format: NLM
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.

Alzheimer's & dementia (New York, N. Y.)

Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, Kinney JW, Tousi B, Leverenz JB, Fillit H, Zhong K, Feldman HH, Cummings J.
PMID: 33614888
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12106. doi: 10.1002/trc2.12106. eCollection 2021.

BACKGROUND: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO-B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective...

Cite
Matthews DC, Ritter A, Thomas RG, et al. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. Alzheimers Dement (N Y). 2021;7(1):e12106doi: 10.1002/trc2.12106.
Matthews, D. C., Ritter, A., Thomas, R. G., Andrews, R. D., Lukic, A. S., Revta, C., Kinney, J. W., Tousi, B., Leverenz, J. B., Fillit, H., Zhong, K., Feldman, H. H., & Cummings, J. (2021). Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. Alzheimer's & dementia (New York, N. Y.), 7(1), e12106. https://doi.org/10.1002/trc2.12106
Matthews, Dawn C, et al. "Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia." Alzheimer's & dementia (New York, N. Y.) vol. 7,1 (2021): e12106. doi: https://doi.org/10.1002/trc2.12106
Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, Kinney JW, Tousi B, Leverenz JB, Fillit H, Zhong K, Feldman HH, Cummings J. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12106. doi: 10.1002/trc2.12106. eCollection 2021. PMID: 33614888; PMCID: PMC7882538.
Copy Download .nbib Format: NLM
The Impact of the COVID-19 Pandemic and Telemedicine Implementation on Practice Patterns and Electronic Health Record Utilization in an Academic Rheumatology Practice.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Maheswaranathan M, Chu P, Johannemann A, Criscione-Schreiber L, Clowse M, Leverenz DL.
PMID: 33843775
J Clin Rheumatol. 2021 Apr 09; doi: 10.1097/RHU.0000000000001751. Epub 2021 Apr 09.

No abstract available.

Cite
Maheswaranathan M, Chu P, Johannemann A, et al. The Impact of the COVID-19 Pandemic and Telemedicine Implementation on Practice Patterns and Electronic Health Record Utilization in an Academic Rheumatology Practice. J Clin Rheumatol. 2021;doi: 10.1097/RHU.0000000000001751.
Maheswaranathan, M., Chu, P., Johannemann, A., Criscione-Schreiber, L., Clowse, M., & Leverenz, D. L. (2021). The Impact of the COVID-19 Pandemic and Telemedicine Implementation on Practice Patterns and Electronic Health Record Utilization in an Academic Rheumatology Practice. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, . https://doi.org/10.1097/RHU.0000000000001751
Maheswaranathan, Mithu, et al. "The Impact of the COVID-19 Pandemic and Telemedicine Implementation on Practice Patterns and Electronic Health Record Utilization in an Academic Rheumatology Practice." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases vol. (2021). doi: https://doi.org/10.1097/RHU.0000000000001751
Maheswaranathan M, Chu P, Johannemann A, Criscione-Schreiber L, Clowse M, Leverenz DL. The Impact of the COVID-19 Pandemic and Telemedicine Implementation on Practice Patterns and Electronic Health Record Utilization in an Academic Rheumatology Practice. J Clin Rheumatol. 2021 Apr 09; doi: 10.1097/RHU.0000000000001751. Epub 2021 Apr 09. PMID: 33843775.
Copy Download .nbib Format: NLM
[Disease-modifying treatment approaches in Huntington disease : Past and future].

Der Nervenarzt

Frank W, Lindenberg KS, Mühlbäck A, Lewerenz J, Landwehrmeyer GB.
PMID: 34762178
Nervenarzt. 2021 Nov 11; doi: 10.1007/s00115-021-01224-8. Epub 2021 Nov 11.

Huntington disease (HD) is the most frequent monogenetic neurodegenerative disease and can be unequivocally diagnosed even in the preclinical stage, at least in all individuals in whom the CAG expansion mutation in the huntingtin gene (HTT) is in the...

Cite
Frank W, Lindenberg KS, Mühlbäck A, et al. Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit : Blicke zurück und Blicke voraus. [Disease-modifying treatment approaches in Huntington disease : Past and future]. Nervenarzt. 2021;doi: 10.1007/s00115-021-01224-8.
Frank, W., Lindenberg, K. S., Mühlbäck, A., Lewerenz, J., & Landwehrmeyer, G. B. (2021). Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit : Blicke zurück und Blicke voraus. [Disease-modifying treatment approaches in Huntington disease : Past and future]. Der Nervenarzt, . https://doi.org/10.1007/s00115-021-01224-8
Frank, Wiebke, et al. "Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit : Blicke zurück und Blicke voraus." [Disease-modifying treatment approaches in Huntington disease : Past and future]. Der Nervenarzt vol. (2021). doi: https://doi.org/10.1007/s00115-021-01224-8
Frank W, Lindenberg KS, Mühlbäck A, Lewerenz J, Landwehrmeyer GB. Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit : Blicke zurück und Blicke voraus. [Disease-modifying treatment approaches in Huntington disease : Past and future]. Nervenarzt. 2021 Nov 11; doi: 10.1007/s00115-021-01224-8. Epub 2021 Nov 11. German. PMID: 34762178.
Copy Download .nbib Format: NLM
Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease.

Genome research

Xu J, Zhang P, Huang Y, Zhou Y, Hou Y, Bekris LM, Lathia J, Chiang CW, Li L, Pieper AA, Leverenz JB, Cummings J, Cheng F.
PMID: 33627474
Genome Res. 2021 Oct;31(10):1900-1912. doi: 10.1101/gr.272484.120. Epub 2021 Feb 24.

Because disease-associated microglia (DAM) and disease-associated astrocytes (DAA) are involved in the pathophysiology of Alzheimer's disease (AD), we systematically identified molecular networks between DAM and DAA to uncover novel therapeutic targets for AD. Specifically, we develop a network-based methodology...

Cite
Xu J, Zhang P, Huang Y, et al. Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. Genome Res. 2021;31(10):1900-1912doi: 10.1101/gr.272484.120.
Xu, J., Zhang, P., Huang, Y., Zhou, Y., Hou, Y., Bekris, L. M., Lathia, J., Chiang, C. W., Li, L., Pieper, A. A., Leverenz, J. B., Cummings, J., & Cheng, F. (2021). Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. Genome research, 31(10), 1900-1912. https://doi.org/10.1101/gr.272484.120
Xu, Jielin, et al. "Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease." Genome research vol. 31,10 (2021): 1900-1912. doi: https://doi.org/10.1101/gr.272484.120
Xu J, Zhang P, Huang Y, Zhou Y, Hou Y, Bekris LM, Lathia J, Chiang CW, Li L, Pieper AA, Leverenz JB, Cummings J, Cheng F. Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. Genome Res. 2021 Oct;31(10):1900-1912. doi: 10.1101/gr.272484.120. Epub 2021 Feb 24. PMID: 33627474; PMCID: PMC8494225.
Copy Download .nbib Format: NLM
CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis.

Neurology(R) neuroimmunology & neuroinflammation

Dürr M, Nissen G, Sühs KW, Schwenkenbecher P, Geis C, Ringelstein M, Hartung HP, Friese MA, Kaufmann M, Malter MP, Madlener M, Thaler FS, Kümpfel T, Senel M, Häusler MG, Schneider H, Bergh FT, Kellinghaus C, Zettl UK, Wandinger KP, Melzer N, Gross CC, Lange P, Dreyhaupt J, Tumani H, Leypoldt F, Lewerenz J.
PMID: 34697224
Neurol Neuroimmunol Neuroinflamm. 2021 Oct 25;8(6). doi: 10.1212/NXI.0000000000001086. Print 2021 Nov.

BACKGROUND AND OBJECTIVES: CSF in antibody-defined autoimmune encephalitis (AE) subtypes shows subtype-dependent degrees of inflammation ranging from rare and often mild to frequent and often robust. AEs with NMDA receptor antibodies (NMDAR-E) and leucine-rich glioma-inactivated protein 1 antibodies (LGI1-E)...

Cite
Dürr M, Nissen G, Sühs KW, et al. CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6)doi: 10.1212/NXI.0000000000001086.
Dürr, M., Nissen, G., Sühs, K. W., Schwenkenbecher, P., Geis, C., Ringelstein, M., Hartung, H. P., Friese, M. A., Kaufmann, M., Malter, M. P., Madlener, M., Thaler, F. S., Kümpfel, T., Senel, M., Häusler, M. G., Schneider, H., Bergh, F. T., Kellinghaus, C., Zettl, U. K., Wandinger, K. P., Melzer, N., Gross, C. C., Lange, P., Dreyhaupt, J., Tumani, H., Leypoldt, F., Lewerenz, J. (2021). CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. Neurology(R) neuroimmunology & neuroinflammation, 8(6), . https://doi.org/10.1212/NXI.0000000000001086
Dürr, Marc, et al. "CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis." Neurology(R) neuroimmunology & neuroinflammation vol. 8,6 (2021). doi: https://doi.org/10.1212/NXI.0000000000001086
Dürr M, Nissen G, Sühs KW, Schwenkenbecher P, Geis C, Ringelstein M, Hartung HP, Friese MA, Kaufmann M, Malter MP, Madlener M, Thaler FS, Kümpfel T, Senel M, Häusler MG, Schneider H, Bergh FT, Kellinghaus C, Zettl UK, Wandinger KP, Melzer N, Gross CC, Lange P, Dreyhaupt J, Tumani H, Leypoldt F, Lewerenz J. CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 25;8(6). doi: 10.1212/NXI.0000000000001086. Print 2021 Nov. PMID: 34697224; PMCID: PMC8546742.
Copy Download .nbib Format: NLM
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis.

Neurology(R) neuroimmunology & neuroinflammation

Tietz AK, Angstwurm K, Baumgartner T, Doppler K, Eisenhut K, Elisak M, Franke A, Golombeck KS, Handreka R, Kaufmann M, Kraemer M, Kraft A, Lewerenz J, Lieb W, Madlener M, Melzer N, Mojzisova H, Möller P, Pfefferkorn T, Prüss H, Rostásy K, Schnegelsberg M, Schröder I, Siebenbrodt K, Sühs KW, Wickel J, Wandinger KP, Leypoldt F, Kuhlenbäumer G.
PMID: 34584012
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 28;8(6). doi: 10.1212/NXI.0000000000001085. Print 2021 Nov.

BACKGROUND AND OBJECTIVES: To investigate the genetic determinants of the most common type of antibody-mediated autoimmune encephalitis, anti-NMDA receptor (anti-NMDAR) encephalitis.METHODS: We performed a genome-wide association study in 178 patients with anti-NMDAR encephalitis and 590 healthy controls, followed by...

Cite
Tietz AK, Angstwurm K, Baumgartner T, et al. Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6)doi: 10.1212/NXI.0000000000001085.
Tietz, A. K., Angstwurm, K., Baumgartner, T., Doppler, K., Eisenhut, K., Elisak, M., Franke, A., Golombeck, K. S., Handreka, R., Kaufmann, M., Kraemer, M., Kraft, A., Lewerenz, J., Lieb, W., Madlener, M., Melzer, N., Mojzisova, H., Möller, P., Pfefferkorn, T., Prüss, H., Rostásy, K., Schnegelsberg, M., Schröder, I., Siebenbrodt, K., Sühs, K. W., Wickel, J., Wandinger, K. P., Leypoldt, F., Kuhlenbäumer, G. (2021). Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis. Neurology(R) neuroimmunology & neuroinflammation, 8(6), . https://doi.org/10.1212/NXI.0000000000001085
Tietz, Anja K, et al. "Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis." Neurology(R) neuroimmunology & neuroinflammation vol. 8,6 (2021). doi: https://doi.org/10.1212/NXI.0000000000001085
Tietz AK, Angstwurm K, Baumgartner T, Doppler K, Eisenhut K, Elisak M, Franke A, Golombeck KS, Handreka R, Kaufmann M, Kraemer M, Kraft A, Lewerenz J, Lieb W, Madlener M, Melzer N, Mojzisova H, Möller P, Pfefferkorn T, Prüss H, Rostásy K, Schnegelsberg M, Schröder I, Siebenbrodt K, Sühs KW, Wickel J, Wandinger KP, Leypoldt F, Kuhlenbäumer G. Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021 Sep 28;8(6). doi: 10.1212/NXI.0000000000001085. Print 2021 Nov. PMID: 34584012; PMCID: PMC8479862.
Copy Download .nbib Format: NLM
Microbial fuel cell treatment energy-offset for fertilizer production from human urine.

Chemosphere

Sabin JM, Leverenz H, Bischel HN.
PMID: 35031247
Chemosphere. 2022 Jan 11;133594. doi: 10.1016/j.chemosphere.2022.133594. Epub 2022 Jan 11.

Microbial fuel cells (MFCs) are a promising technology for simultaneous wastewater treatment and the biological conversion of organics to electrical energy. Yet effective MFC utilization of complex waste streams like human urine is limited by interference from high-strength organics...

Cite
Sabin JM, Leverenz H, Bischel HN. Microbial fuel cell treatment energy-offset for fertilizer production from human urine. Chemosphere. 2022;133594doi: 10.1016/j.chemosphere.2022.133594.
Sabin, J. M., Leverenz, H., & Bischel, H. N. (2022). Microbial fuel cell treatment energy-offset for fertilizer production from human urine. Chemosphere, 133594. https://doi.org/10.1016/j.chemosphere.2022.133594
Sabin, Jeanne M, et al. "Microbial fuel cell treatment energy-offset for fertilizer production from human urine." Chemosphere vol. (2022): 133594. doi: https://doi.org/10.1016/j.chemosphere.2022.133594
Sabin JM, Leverenz H, Bischel HN. Microbial fuel cell treatment energy-offset for fertilizer production from human urine. Chemosphere. 2022 Jan 11;133594. doi: 10.1016/j.chemosphere.2022.133594. Epub 2022 Jan 11. PMID: 35031247.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 64 entries